Powered by HealthTechMovers.com
We added 1 stock to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Akero Therapeutics, AKRO
Summary: Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States.
- Last Price: $48.46
- Price Change: -$0.14, -0.29%
- Yearly Gain: 83.81%
- Market Cap: $2.70B
- P/E Ratio: -18.97
Here are 3rd party ratings for AKRO:
- TipRanks.com: Strong Buy
- TradingView.com: neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 39% (96 out of 246)
What is the sentiment on the street regarding Akero Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in AKRO or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on AKRO before you decide to make any investment.
Click here for chart >>
Thanks for reading!
